MICROCYTOXICITY ASSAY BY PRE-LABELING TARGET CELLS

专利名称：MICROCYTOXICITY ASSAY BY PRE-
LABELING TARGET CELLS
发明人：Nikola L. VUJANOVIC
申请号：US11733863
申请日：20070411
公开号：US20080254480A1
公开日：
20081016
专利内容由知识产权出版社提供
专利附图：
摘要：The standard or original microcytotoxicity assay (OMCA) has significant
advantages over other cytotoxicity assays, since it is able to detect both cell necrosis and apoptosis and it is simpler, safer, more practical, and more economical. OMCA has serious
weaknesses, however, such as low accuracy, low selectivity, and low sensitivity. These drawbacks are ameliorated or eliminated by pre-labeling of target cell nuclei, for instance, with 5-bromo2′-deoxyuridine. This improved microcytotoxicity assay (IMCA) is readily adapted to a wide range of applications, such as screening of cytotoxicity drug candidates, selecting an anticancer cytotoxic therapy, detecting abnormalities including reduced tumor cell killing ability of NK cells in cancer patients, predicting outcome of cytokine therapy and immunotherapy, determining effectiveness of cytokine therapy and immunotherapy in follow up studies following treatment, determining effectiveness of anticancer cytotoxic therapy during and following therapy and ascertaining cytotoxic T cell activity during anticancer vaccination therapy.
申请人：Nikola L. VUJANOVIC
地址：Pittsburgh PA US
国籍：US
更多信息请下载全文后查看。